CRGX Stock Overview
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CARGO Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.96 |
| 52 Week High | US$33.92 |
| 52 Week Low | US$13.14 |
| Beta | 0 |
| 1 Month Change | 0.24% |
| 3 Month Change | -10.81% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 44.25% |
Recent News & Updates
Shareholder Returns
| CRGX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.7% | 2.7% | 0.3% |
| 1Y | n/a | 2.9% | 24.2% |
Return vs Industry: Insufficient data to determine how CRGX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CRGX performed against the US Market.
Price Volatility
| CRGX volatility | |
|---|---|
| CRGX Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CRGX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CRGX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 116 | Gina Chapman | cargo-tx.com |
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company’s lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets.
CARGO Therapeutics, Inc. Fundamentals Summary
| CRGX fundamental statistics | |
|---|---|
| Market cap | US$808.63m |
| Earnings (TTM) | -US$98.15m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.4x
P/E RatioIs CRGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRGX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$98.15m |
| Earnings | -US$98.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.49 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CRGX perform over the long term?
See historical performance and comparison